Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ, TRACERx Renal Consortium. · 2018

Read Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. by Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ, TRACERx Renal Consortium. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5927631.txt.

Introduction

Mitchell and co-authors time the landmark events in clear cell kidney cancer. Their article appeared in Cell. They analysed whole genomes from 95 biopsies. Samples came from 33 patients with this cancer type. Loss of chromosome 3's short arm marks nearly every case. That loss removes several tumour suppressor genes at once.

The key event often strikes in childhood or teens, they report. It can precede the tumour's common ancestor by decades. A shattering event often causes both the loss and a gain elsewhere. Inherited cases follow the same early pattern. Very few cells with the loss can start sporadic tumours. Early trajectories may offer chances for early action.

Catalog record

CREATORMitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ, TRACERx Renal Consortium.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE97 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5927631

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal By Thomas J Mitchell, Samra Turajlic, Andrew Rowan, David Nicol, James HR Farmery, Tim O’Brien, Inigo Martincorena, Patrick Tarpey, Nicos Angelopoulos, Lucy R Yates, Adam P Butler, Keiran Raine Published in: Cell DOI: 10.1016/j.cell.2018.02.020 ABSTRACT Summary Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma. We find hotspots of point mutations in the 5′ UTR of TERT, targeting a MYC-MAX-MAD1 repressor associated with telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. This event occurs in childhood or adolescence, generally as the initiating event that precedes emergence of the tumor’s most recent common ancestor by years to decades. Similar genomic changes drive inherited ccRCC. Modeling differences in age incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Early development of ccRCC follows well-defined evolutionary trajectories, offering opportunity for early intervention. Keywords: clear cell renal cell carcinoma, cancer evolution, chromothripsis INTRODUCTION Cancers of the kidney develop in an estimated 300,000 people worldwide every year, with approximately half dying from the disease (Fitzmaurice et al., 2015). The commonest histological subtype is clear cell renal cell carcinoma (ccRCC), a tumor believed to arise from the epithelial cells of the proximal convoluted tubule of the nephron (Frew and Moch, 2015). The genome of clear cell renal cell carcinoma is distinctive. Loss of the short arm of chromosome 3 is the critical genetic event, found in >90% patients (Beroukhim et al., 2010, Shen et al., 2011, Cancer Genome Atlas Research Network, 2013, Zbar et al., 1987). The deleted region always encompasses four tumor suppressor genes that are frequent targets for inactivating point mutations on the other chromosomal copy: VHL (point mutations in 60%–70% patients; epigenetic silencing in a further 5%–10%), PBRM1 (40%), BAP1 (10%), and SETD2 (10%) (Dalgliesh et al., 2010, Sato et al., 2013, Cancer Genome Atlas Research Network, 2013, Varela et al., 2011). The second most frequent genetic event in clear cell renal cell carcinoma is gain of chromosome 5q, seen in 65%–70% of patients (Beroukhim et al., 2010, Shen et al., 2011, Cancer Genome Atlas Research Network, 2013), with SQSTM1 one of the likely target genes (Li et al., 2013). Recent exome sequencing studies have highlighted the considerable intra-tumoral heterogeneity of clear cell renal cell carcinomas (Gerlinger et al., 2012, Gerlinger et al., 2014). In growing to sizes of several centimeters in diameter, these tumors often comprise several geographically localized subclones. Interestingly, chromosome 3p loss and, when present, VHL point mutations are always on the trunk of the phylogenetic tree, suggesting that they are key early events in cancer development. Studies of somatic mutations in clear cell renal cell carcinoma to date have primarily focused on protein-coding genes. As a result, the mechanism of chromosome 3p loss has not been well characterized, nor the role of non-coding driver mutations. Here, using a multi-region sampling approach, we report whole genome sequences from 95 clear cell renal cell carcinoma biopsies across 33 patients. RESULTS Whole-Genome Sequencing of Clear Cell Renal Cell Carcinomas TRACERx Renal is a prospective cohort study of patients with RCC, which aims to assess the evolutionary trajectories of clear cell renal cell carcinoma (Turajlic and Swanton, 2017). In particular, multi-region sampling of the primary cancer and any metastases is used to generate high-resolution information on the timing of driver mutations, level of intratumoral heterogeneity, and presence of parallel evolution in each patient. To date, 100 patients in TRACERx Renal have been profiled with exome and targeted gene sequencing and these data are presented in the companion papers to this one (Turajlic et al., 2018a, Turajlic et al., 2018b). We performed whole genome sequencing to an average 67x depth on 128 kidney biopsies, together with matched germline DNA, from 36 patients. The tumor cell fraction was not sufficient in 33 biopsies (including 17 biopsies from normal adjacent kidney) to accurately call somatic aberrations—the dataset analyzed here therefore represents whole genomes of 95 cancer biopsies from 33 patients (Table S1). Clinically, the patients had the typical age range, stage, and size of tumors for sporadic clear cell renal cell carcinoma (Table S2). We used our validated bioinformatics pipelines to identify somatic substitutions, indels, copy number alterations, and structural variants (Campbell et al., 2008, Jones et al., 2016, Raine et al., 2015, Raine et al., 2016). We identified an average of 7,680 unique somatic substitutions and 1,193 indels per patient, but with a 3-fold variation in numbers across patients (Figure 1A; Table S2). The landscape of coding driver mutations and recurrent copy number alterations was typical for clear cell renal cell carcinoma (Figure 1B). There was a high level of concordance between driver mutation calls made in whole genome and targeted panel sequencing (STAR Methods). [Figure: The Clonality of Driver Events and the Relative Timing of 3p Loss in Clear Cell Renal Cell Carcinoma(A) Mutation burden for 34 independent tumors derived from 33 patients. For each tumor, the number of mutations present in the most recent common ancestor and each of the terminal subclones are annotated. The estimated mutational time at which chromosome 3p is lost with 95% CIs has been annotated for those tumors harboring unbalanced translocations with 3p. One patient (K097) developed two independent tumors denoted K097_1 and K097_2.(B) Presence and clonality of driver mutations and copy number aberrations. Driver mutations include those previously reported and that are present in at least 3 independent tumors from this cohort. For cases where a clonal mutation in the WGS data has been detected as subclonal in the more spatially detailed panel data (Turajlic et al., 2018a, Turajlic et al., 2018b), the mutation has been amended in this figure as subclonal.See also Tables S1 and S2.] Non-coding Driver Mutations in the 5′ UTR of TERT Whether there are driver mutations in non-coding regions of the genome has not been extensively explored in clear cell renal cell carcinoma. We assessed these using a model of the background mutation rate across the genome that combines the observed mutation spectrum with genome-wide covariates known to affect mutation rate (Martincorena et al., 2017, Nik-Zainal et al., 2016) (Table S3). Only one non-coding region had a statistically significant excess of mutations: the 5′ UTR and promoter of the telomerase reverse transcriptase gene, TERT (q = 0.016). This region harbored somatic mutations in 5 patients from our cohort of 33 (15%) (Figure 2A), of which two were subclonal. Interestingly, the mutation sites observed in our clear cell renal cell carcinoma data included three positions in the 5′ UTR of TERT, located 15, 24, and 29 base pairs downstream of the transcription start site (Figure 2A). These are different positions from the canonical promoter hotspots mutated in TERT across a wide range of cancers, especially melanomas (Horn et al., 2013, Huang et al., 2013), although we did see mutations at these sites as well (Figure 2A). In chromophobe renal

Read the complete text